Dr. Reddy's Laboratories Limited is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India. The company serves patients in over 150 countries with high-quality, affordable healthcare solutions.
Erez Israeli is the Chief Executive Officer (CEO) at Dr Reddy's Laboratories since 1 Aug 2019. The company operates as a global pharmaceutical corporation with a significant presence in multiple international markets, focusing on providing affordable and innovative medicines for healthier lives.
The Company's segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. Global Generics Segment (~83% of revenues in FY22) Co. offers 400+ high-quality generic drugs, keeping costs reasonable by leveraging its integrated operations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company's business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
The company has established itself as a major player in the biosimilars space and continues to expand its capabilities in this high-growth segment. The company benefits from its expertise in active ingredients, product development skills, a keen understanding of regulations and intellectual property rights & streamlined supply chain.
Dr Reddy's Labs · Mkt Cap: 1,09,113 Crore (up 0.26% in 1 year) · Revenue: 32,644 Cr · Profit: 5,725 Cr · Promoter Holding: 26.6% Dr Reddys Laboratories Ltd has a market capitalisation of Rs 1,08,748 crore. The company has demonstrated strong financial performance with robust revenue growth and profitability.
For the quarter ended March 2025 (Q4FY25), The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24.
Financial highlights include:
- Dr. Reddy's Laboratories has an operating revenue of Rs. 32,643.90 Cr. on a trailing 12-month basis.
- An annual revenue growth of 17% is outstanding, Pre-tax margin of 23% is great, ROE of 16% is good.
- The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet.
Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200 Nifty 500 Nifty Pharma Nifty 100 Nifty 200 Nifty Low Volatility 50 Nifty50 Value 20 Nifty 100 Equal Weight BSE Allcap BSE LargeCap BSE India Manufacturing Index BSE SENSEX 50 Nifty100 Quality 30 BSE 100 ESG Index (INR) BSE 250 LargeMidCap Index BSE Dividend Stability Index BSE Low Volatility Index Nifty 50 Equal Weight Nifty 100 Low Volatility 30 BSE 100 LargeCap TMC Index Nifty LargeMidcap 250 Nifty 500 Multicap 50:25:25 Nifty Healthcare Index Nifty100 ESG Nifty India Manufacturing Nifty Total Market Nifty Alpha Low-Volatility 30 Nifty500 Multicap India Manufacturing 50:30:20 Nifty Quality Low-Volatility 30 Nifty Alpha Quality Low-Volatility 30 Nifty Alpha Quality Value Low-Volatility 30 Nifty500 Equal Weight Nifty500 LargeMidSmall Equal-Cap Weighted Nifty500 Multifactor MQVLv50 The stock is a constituent of several major indices, reflecting its significance in the Indian equity market.
The Dr Reddys Laboratories Ltd's 52-week high share price is Rs 1,420.20 and 52-week low share price is Rs 1,025.90. The stock has shown resilience and growth potential over various time periods, with the company maintaining its position as a leading pharmaceutical stock in India.
The company continues to focus on innovation and expansion. The company is investing in GLP-1RA generics and expanding its consumer health base through acquisitions and partnerships. Dr Reddy's Laboratories announced a collaboration with Alvotech to develop a Keytruda biosimilar, boosting its oncology portfolio.
the newly announced JV with Nestle in 2024 in the nutraceuticals space where both DRL and Nestle will transfer their nutraceutical products to the JV company for sale in the Indian market. This strategic partnership demonstrates the company's commitment to diversifying its product portfolio and expanding into new therapeutic areas.
The company faces some regulatory challenges, with the US FDA had conducted a GMP inspection at its API manufacturing facility in Miryalaguda, Telangana, India. The inspection was conducted from 19 May 2025 to 24 May 2025. Post the inspection, the American regulatory agency has issued a Form 483 with 2 observations.
Dr Reddy's Laboratories has established a strong global footprint with operations spanning multiple continents. The company's strategy focuses on leveraging its cost-effective manufacturing capabilities while maintaining high quality standards to serve both developed and emerging markets. The company's approach to research and development enables it to compete effectively in the global generics market while also building capabilities in more complex therapeutic areas.
The pharmaceutical industry continues to present both opportunities and challenges, with evolving regulatory landscapes and increasing competition. Dr Reddy's Laboratories is well-positioned to navigate these dynamics through its diversified product portfolio, strong financial position, and strategic partnerships that enhance its competitive capabilities across key markets.
